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degradation of cytosolic PrPs and restores the
cytosolic PrP-induced cytotoxicity via a molecular
interaction
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Background: Although the aggregation of PrPSc is thought to be crucial for the neuropathology of prion diseases,
there is evidence in cultured cells and transgenic mice that neuronal death can be triggered by the accumulation
of cytosolic PrPs, leading to the hypothesis that the accumulation of PrPs in the cytosol of neurons may be a
primary neurotoxic culprit. Hsp70, a molecular chaperone involved in protein folding/refolding and degradation in
the cytoplasm, has a protective effect in some models of neurodegenerative diseases, e.g., Alzheimer’s and
Parkinson’s diseases, but its role in prion diseases remains unclear.
Results: To study the role of Hsp70 in prion diseases, we used immunoprecipitation to first identify a molecular
interaction between Hsp70 and PrPs. Using immunofluorescence, we found that Hsp70 colocalized with cytosolic
PrPs in HEK293 cells transiently transfected with plasmids for Cyto-PrP and PG14-PrP but not with wild-type PG5-PrP
or endoplasmic reticulum (ER)-retained PrPs (3AV-PrP and ER-PrP). Using western blot analysis and apoptosis assays
of cultured cells, we found that the overexpression of Hsp70 by transfection or the activation of Hsp70 by
geldanamycin selectively mediated the degradation of cytosolic PrPs and restored cytosolic PrP-induced
cytotoxicity. Moreover, we found that Hsp70 levels were up-regulated in cells expressing Cyto-PrP and in hamster
brains infected with the scrapie agent 263K.
Conclusion: These data imply that Hsp70 has central role in the metabolism of cytosolic PrPs
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Human prion diseases include Creutzfeldt-Jakob disease
(CJD), kuru, fatal familial insomnia (FFI) and Gerstmann-
Straussler-Scheinker syndrome (GSS). The conversion of
the normal cellular prion protein (PrPC) into an insoluble
and protease-resistant isoform (PrPSc), which propagates
itself by imposing its abnormal conformation onto a PrPC,* Correspondence: dongxp238@sina.com
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reproduction in any medium, provided the oris fundamental to the pathogenesis of prion diseases. It
has been commonly assumed that aggregation of mis-
folded PrPSc is the cause of neurodegeneration in prion
diseases [1]. However, in several studies, significant path-
ology and clinical dysfunctions can develop even when
there is little accumulation of PrPSc. Similarly, the accu-
mulation and a high abundance of PrPSc has been accom-
panied by limited symptomatology [2]. These data suggest
that PrPSc may not be the major cause of neuronal dys-
function in prion diseases.
Studies of mutant PrP molecules associated with
inherited prion diseases support the hypothesis that PrPs
that are mislocalized to the cytoplasm acquire neuro-
toxic potential [3]. PG14-PrP, a PrP mutant with an extraLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prion disease in humans, can form numerous aggregates
in neutrophils, is highly neurotoxic and promotes progres-
sive neurodegenerative disease in transgenic Tg (PG14)
mice [4]. Mice expressing a PrP mutant lacking the N-
terminal ER targeting signal (Cyto-PrP) acquired severe
ataxia due to the rapid degeneration of cerebellar granule
neurons [5]. 3AV-PrP is an artificial PrP mutant with three
alanine to valine mutations in the hydrophobic domain.
3AV-PrP substantially increases the hydrophobicity,
remains intracellular at either the ER or Golgi, and causes
neurodegeneration in transgenic mice [6]. Expediting the
removal of these mislocalized PrPs may be a relevant
therapeutic strategy to reduce neurotoxicity.
Heat shock proteins (HSPs) belong to the family of
chaperones and have important roles in regulating the
refolding and degradation of misfolded/mislocalized pro-
teins [7,8]. Hsp70 is the most studied member of the
cytoplasmic HSP family. Recent studies in several neuro-
degeneration models, including Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Huntington’s disease (HD),
suggest that the overexpression of Hsp70 can be protect-
ive. In various cellular models for AD, increasing the levels
of Hsp70 inhibited the propensity of Aβ to aggregate and
reduced the toxicity of Aβ. Hsp70 also promoted the solu-
bility of tau and its binding to microtubules [9]. The ag-
gregation of α-synuclein is a hallmark of sporadic and
familial PD. The overexpression of Hsp70 prevented
neuronal loss by inhibiting α-synuclein fibril formation
[10]. In a yeast model for HD, the expression of Hsp70
reduced the toxicity associated with the expression of mu-
tant huntingtin (htt) by preventing its aberrant interaction
with an essential polyQ-containing transcription factor
[11]. It remains unclear whether Hsp70 also plays a role in
prion diseases.
Hsp70 is one of the most potent molecular chaperones.
In this study, we present evidence that Hsp70 is able to
directly interact with PrPs. Colocalization studies indicate
that the cytosolic forms of mutant PrPs are the targets of
Hsp70. Furthermore, we found that the overexpression or
activation of Hsp70 in cultured cells selectively mediated
the degradation of cytosolic PrPs and contributed to the
protective effect against cytotoxicity induced by cytosolic
PrPs. These data implicate Hsp70 as a central regulator in
the metabolism of cytosolic PrPs.
Materials and methods
Ethics statement
The use of animal specimens in this study was approved
by the Ethical Committee of the National Institute for
Viral Disease Prevention and Control, China CDC under
protocol 2009ZX10004-101. All Chinese golden ham-
sters were maintained under clean conditions. Housing
and experimental protocols were performed in accordancewith the Chinese Regulations for the Administration of
Affairs Concerning Experimental Animals.
Plasmids and reagents
Mammalian expression plasmids for human wild-type
PrP (PG5-PrP), Cyto-PrP, CtmPrP (3AV-PrP), 9 extra
octarepeats inserted PrP (PG14-PrP) and PrP-KDEL
(ER-PrP) were constructed in the vector pcDNA3.1+ as
described elsewhere [12]. The plasmid pEGFP-Hsp70
was obtained from Addgene (Cambridge, MA) [13]. The
antibody to PrP (3F4) was from Millipore (Billerica,
MA). Antibodies to β-actin (sc-47778) and Hsp70
(sc-1060) were from Santa Cruz (Santa Cruz, CA). Anti-
body to Calnexin (208880) was from Merck Millipore
(Billerica, MA). The HRP-conjugated anti-goat and anti-
mouse IgG were from Boehringer (Germany). The Alexa
Fluor 568 goat anti-mouse IgG was from Invitrogen (USA).
Geldanamycin (cat# 345805) and MG132 (474790) were
purchased from Calbiochem (San Diego, CA).
Transfection
Cell lines, including human embryonic kidney (HEK)
293 (CRL-1573) cells and mouse neuroblastoma Neuro-
2a (CCL-131) cells, were maintained in Dulbecco’s
modified Eagle’s culture medium supplemented with
10% fetal calf serum. The various recombinant plasmids
were transiently transfected into HEK 293 or N2a cells
using Lipofectamine 2000 (Invitrogen).
RNA Interference
RNA interference was carried out using siRNA purchased
from Invitrogen. The siRNA corresponding to the Hsp70
mRNA sequences 5’-AGG ACG AGU UUG AGC ACA
ATT-3’ was used to inhibit endogenous Hsp70 protein ex-
pression. The negative control siRNA has no relation with
human gene (sense siRNA3, 5’-UUC UCC GAA CGU
GUC ACG UTT-3’ and antisense siRNA3, 5’-ACG UGA
CAC GUU CGG AGA ATT-3’). Various siRNAs were
transfected into HEK 293 cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Cells were collected for further
experiments 72 h after transfection.
Preparation of hamster brain homogenates and cell
lysates
Hamster brain tissues were homogenized in cold lysis
buffer (1% Nonidet P-40, 50 mM HEPES, pH 7.6, 10% gly-
cerol, 1 mM EDTA, 20 mM β-glycerophosphate, 1 mM
sodium orthovanadate, 1 mM sodium metabisulfite, 1 mM
benzamidine hydrochloride, 10 μg/ml leupeptin, 20 μg/ml
aprotinin and 1 mM phenylmethylsulfonyl fluoride),
followed by sonication [14]. Cultured cells treated with
different transfections or reagents were harvested, and
the whole cell lysates were prepared in cold lysis buffer
with sonication. After centrifugation at 10,000 × g at
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ther experiments.
Western blots
Cellular lysates or brain homogenates were separated by
12% SDS-PAGE and electro-transferred onto nitrocellu-
lose membranes. After blocking with 5% nonfat-dried
milk in PBST (phosphate buffered saline, pH 7.6, con-
taining 0.05% Tween-20), the membranes were incu-
bated with a PrP-specific monoclonal antibody (mAb)
3F4 (Millipore), diluted 1:4000; a mAb to Hsp70, diluted
1:2000; or a mAb to human β-actin (Santa Cruz), diluted
1:2000. Subsequently, the membranes were incubated
with HRP-conjugated anti-mouse IgG or anti-goat IgG,
diluted 1:10,000. The reactive signals were visualized by
ECL (PE Applied Biosystems, Foster City, USA). Immu-
noblots were quantified using a scanning densitometer
in conjunction with the NIH ImageJ software. The sig-
nals were normalized to the loading controls.
Immunoprecipitations
Immunoprecipitations (IPs) were carried out using whole
cell lysates (400 μg of total protein), 2–4 μg of antibody
and 20 μl of DynabeadsW-coated Protein G (Invitrogen).
The cell lysates were mixed with different antibodies at 4°C
for 3–4 h and subsequently incubated with DynabeadsW-
coated Protein G for another 2 h. The immunocomplexes
were collected by a short spin and washed five times in
wash buffer before being resolved by SDS-PAGE. The
complexes were detected by Western blotting.
Apoptosis assays
The situations of the mitochondrial transmembrane
transition in live cells were determined with a MitoCap-
tureTM Mitochondrial Apoptosis Detection kit, BioVi-
sion (Plymouth meeting, PA, USA) according to the
manufacturer’s instruction. Growing cells (approximately
60% confluence) were transiently transfected with vari-
ous recombinant plasmids. The cells were collected 48 h
after the transfection, resuspended in 1 ml of diluted
MitoCapture solution, and then incubated at 37°C for
20 min. After a short spin, the cells were resuspended in
1 ml of pre-warmed incubation buffer. The cells were
mounted onto glass coverslips and examined using
fluorescence microscopy (Olympus BX51, Japan). The
total number of cells in a field of view were counted
using ImageJ. Apoptotic and healthy cells displayed as
green and red, respectively. The percentage of apoptotic
cells was defined as the number of green cells vs. the
total number of cells.
Immunofluorescence staining
The cells were fixed with formaldehyde (4% paraformal-
dehyde, freshly depolymerized in 0.1 M sodium phosphatebuffer, pH 7.4) at RT for 15 min and washed three times
in PBS. The cells were blocked with blocking buffer (PBS
with 5% FBS and 0.1% Triton X-100) at RT for 1 h and
then incubated with a 1:200 dilution of anti-PrP mAb in
PBS with 2% BSA and 0.3% Triton X-100 at 4°C overnight.
The cells were then washed and incubated with a 1:200 di-
lution of the appropriate secondary antibody (Alexa
FluorW 568 Goat anti-Mouse, Invitrogen) at RT for 2 h.
After washing, the cells were incubated with 0.5 mg/ml
DAPI (Invitrogen) at RT for 2 min. The cells were sealed,
and images of the targeting proteins were analyzed using
confocal microscopy (Leica ST2, Germany).
Extract subcellular proteomes
Cells were fractionated into cytosol, membranes/organ-
elle mitochondria, nuclei, and cytoskeleton using Subcel-
lular ProteoExtract kit from Merck Millipore according
to the manufacturer's directions.
Statistical analysis
In this study, all of the experiments were conducted at
least 3 times with consistent results. The mean value
and standard error of multiple data points or samples
were used to represent the final result. Student’s t test
was used for statistical analysis and a P < 0.05 was con-
sidered significant.
Results
The identification of cytosolic PrPs as a target for Hsp70
Hsp70 is required as a structural component of refold-
ing/degradation complexes to correct or clear several
misfolded amyloidogenic proteins involved in neurode-
generative diseases. To determine if Hsp70 interacts
with PrPs, HEK293 cells without detectable cellular PrPs
were co-transfected with pcDNA-PrP-PG5 and pEGFP-
Hsp70. Western blots of the cell lysates revealed two
Hsp70-specific bands at 70 and 90 kDa, representing the
endogenous Hsp70 and recombinant EGFP-Hsp70, re-
spectively. In addition, PrP-specific signals were detected
at 25–35 kDa (Figure 1). When PrPs were immunopreci-
pitated from the cell lysates and subjected to Western
blot analysis, two Hsp70 bands were detected (Figure 1A).
Similarly, when Hsp70 was immunoprecipitated and sub-
jected to Western blot analysis, PrP specific signals were
detected (Figure 1B). Neither Hsp70 nor PrP were detect-
able in the cell lysates immunoprecipitated with isotype
IgG. These results suggest that PrP can form a complex
with Hsp70 in cell lysates.
Normally, PrPC is predominantly localized to the cell
surface, but some PrP mutants are retained and aggre-
gate in the cytoplasm. To determine if Hsp70 colocalizes
with different PrP mutants in the cytoplasm, we used
immunofluorescence to examine HEK293 cells trans-
fected with plasmids containing wild-type or various
Figure 1 The cytosolic forms of PrP were targets of Hsp70. A and B. Immunoprecipitation assays. HEK293 cells were co-transfected with
pcDNA-PrP-PG5 and pEGFP-Hsp70. Forty-eight hours after the transfection, the cells were harvested, and 400 μg of the whole cell lysate proteins
was used in the immunoprecipitation assays. In (A), PrP was immunoprecipitated and blotted with anti-Hsp70. In (B), Hsp70 was
immunoprecipitated and blotted with anti-PrP. C. Immunofluorescence. HEK293 cells co-transfected with pEGFP-Hsp70, and various PrP plasmids
were stained for 48 h. The individual and merged images of PrP (red), Hsp70 (green), DAPI (blue) were monitored under confocal microscopy.
The preparations of the various PrP constructs are indicated on the left. D. The cells infected with various PrP plasmids were extracted subcellular
proteomes and examined separately by Western blot analysis using PrP-, Hsp70- and Calnexin-specific antibodies. C: cytosol fraction M:
membrane/organelle fraction. E. Immunoprecipitation assays of cytosol fraction. The cytosol fractions extracted from the cells transfected with
various PrP plasmids were to be immunoprecipitated by anti-PrP and blotted with anti-Hsp70.
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most of the wild-type PrPs (PG5-PrP) localized to the cell
surface; ER-retained PrP mutants (3AV-PrP and ER-PrP)
formed large plaque-like structures with strong signal in-
tensities in the cytoplasm, while Cyto-PrP and PG14-PrP
were found in numerous round particles in the cytoplasm.
Interestingly, the distribution of Hsp70 in the cytoplasm
was obviously influenced by the different PrP constructs.
In the cells expressing PG5-PrP, as well as 3AV-PrP and
ER-PrP, Hsp70 was dispersed in the cytoplasm and did
not significantly colocalize with the 3AV-PrP or ER-PrP-
formed deposits. However, in the cells expressing Cyto-PrP
or PG14-PrP, Hsp70 colocalized well with the PrP-specific
particles in the cytoplasm. The degree of colocalization be-
tween Hsp70 and PrP increased in the cells expressing
Cyto-PrP. (Figure 1C). To see the distributions of different
PrP constructs in various subcelluar fractions, the cytosolic
and membrane/organelle protein fractions were separately
extracted with ProteoExtractW Subcellular Proteome Ex-
traction Kit (S-PEK). It showed that the majorities of Cyto-
PrP and PG14-PrP presented in the cytosolic fraction,
whereas PG5-PrP, 3AV-PrP and ER-PrP were mainly de-
tectable in the membrane/organelle protein fraction(Figure 1D). As expected, cellular Hsp70 was observed in
the cytosolic fraction. Subsequent immunoprecipitation
experiments of the cytosolic fractions of various PrP
preparations confirmed the associations between Hsp70
and cytosolic PrP (Cyto-PrP and PG14-PrP), but not in
those of other PrP constructs (PG5-, 3AV- and ER-PrP)
(Figure 1E).
Hsp70 selectively reduced the levels of the cytosolic
forms of the PrP mutants
To explore the possible role of Hsp70 in regulating the
degradation of various PrPs, we transfected HEK293 and
N2a cells with different PrP-expressing plasmids and
compared the levels of the PrPs by Western blot ana-
lysis. The cells were also treated with geldanamycin
(GA), an Hsp90 inhibitor and can indirectly induce
Hsp70 expression [15], or co-transfected with the plas-
mid pEGFP-Hsp70. As expected, the addition of GA
increased the levels of endogenous Hsp70 (detected at
70 kDa) while transfection with pEGFP-Hsp70 led to the
expression of EGFP-Hsp70 (detected at 90 kDa) in
HEK293 and N2a cells (Figure 2A and B). Compared to
the controls transfected with PrP-expressing plasmids
Figure 2 Hsp70 selectively reduced the levels of the cytosolic forms of PrP mutants. A and B. Western blots. HEK293 (A) and N2a cells (B)
were transiently co-transfected with pEGFP-Hsp70 and various PrP-plasmids. Twenty-four hours after transfection, the cells were treated with or
without geldanamycin (1 μM) for an additional 24 h. The cells were harvested and examined separately by Western blot analysis using PrP- or
Hsp70-specific antibodies. C and D. Quantification of the immunoblots. The numerical gray values for PrP were quantified and normalized to
β-actin levels in HEK293 cells (C) and N2a cells (D). All experiments presented in the figures were repeated independently 3 times with consistent
results. Each data point represents the mean ± SEM of 3 independent experiments. Samples were considered statistically different from the
controls when P < 0.05.
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remained unchanged while the levels of Cyto-PrP and
PG14-PrP decreased in HEK293 (Figure 2A) and N2a
cells (Figure 2B) treated with GA or transfected with
pEGFP-Hsp70. The relative gray values of the PrP sig-
nals were quantified and normalized to β-actin levels
and revealed significantly lower levels of Cyto-PrP and
PG14-PrP in cells treated with GA or transfected with
pEGFP-Hsp70 (Figure 2C and D). The result suggests
that Hsp70 selectively regulates the metabolism of the
cytosolic forms of PrPs but has little effect on the wild-
type and ER-retained PrPs.
Cytosolic PrP degradation mediated by Hsp70 is
dependent on ubiquitination and proteasome
To further confirm the role of Hsp70 related to the
degradations of cytosolic PrPs, a pair of Hsp70 specific
RNAi sequences was synthesized according to thepublished literature [16]. HEK293 cells were co-transfected
with cytosolic PrP constructs (Cyto-PrP or PG14-PrP) and
Hsp70 specific RNAi or a commercial negative control
RNAi which was assumed to be unable to interfere in the
expression of cellular protein. In the cells expressing
Hsp70 specific RNAi, the cellular endogenous Hsp70 pro-
tein was obviously reduced (Figure 3A), reaching to ap-
proximately 60% compared with the cells receiving
negative control RNAi. Accompanying with the reduction
of Hsp70, both Cyto-PrP and PG14-PrP in the cells expres-
sing Hsp70 RNAi were remarkably increased, compared to
those with negative control RNAi (Figure 3A). It indicates
that the specific knockdown of the cellular endogenous
Hsp70 efficiently block the degradations of cytosolic forms
of PrP proteins.
Chaperone proteins-induced misfolded/mislocalized pro-
teins reduction is often a result of ubiquitination-
mediated protein degradation. To address whether the
Figure 3 Ubiquitination and proteasome-mediated degradation. A. RNA inference. siRNAs for both Hsp70 and negative control RNA were
used. HEK293 cells were co-transfected with different siRNA and the plasmid expressing PG14-PrP or Cyto-PrP and harvested 48 h post-
transfection. The cell lysates were examined by PrP- and Hsp70-specific Western blots. B. Proteasome effect. HEK293 cells were transiently
transfected with the plasmid PG14-PrP or Cyto-PrP. 48 h later, 1 μM GA (final concentration) was added into the culture medium and maintained
for another 24 h and 30 μM MG132 (final concentration) was added at the last 6 h. The levels of PrP and actin in the cell lysates were evaluated
by individual Western blots. C. Ubiquitination. HA-ubiquitin and various PrPs were transiently expressed in HEK293 cells in the presence or
absence of 1 μM GA. Cells lysates were employed into immunoprecipitation captured with anti-PrP antibody. Ubiquitinated proteins were
evaluated by ubiquitin specific Western blots.
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PrP proteins underwent above pathway, the cell lysates
of Cyto-PrP and PG14-PrP were subjected to the subse-
quent tests for evaluating the modifications of ubiquiti-
nation and proteasome. Western blots revealed that in
the presence of GA, both Cyto-PrP and PG14-PrP were
clearly down-regulated, while co-treatment of the cells
with MG132, a proteasome inhibitor, was capable of re-
versing the GA-mediated reductions of Cyto-PrP and
PG14-PrP partially (Figure 3B). To see the ubiquitina-
tion status of different PrP proteins, a recombinant plas-
mid expressing HA-tagged ubiquitin (Ub) was transfected
into HEK293 cells together with various PrP expressing
plasmids. Immunoprecipitation assays using PrP mAb 3F4
as the capturing antibody and ubiquitin pAb as the detect-
ing one showed that in the presence of GA, the signals of
the ubiquitinated proteins maintained almost unchanged
in the cells expressing wild-type PrP (PG5-PrP) compared
to that without GA treatment, while those in the cells
expressing Cyto-PrP or PG14-PrP increased markedly, es-
pecially in the expected regions of the expressing PrPs
(Figure 3C). The data suggest that the derogations of thecytosolic PrPs are mediated by Hsp70 in proteasome after
modification by ubiquitination.GA selectively reversed apoptosis induced by the
cytosolic forms of PrP mutants
To examine the effect of increasing cellular Hsp70 levels
on reversing the cytotoxicity of the PrP mutants, the
Hsp70 inducer GA was introduced into HEK293 and
N2a cells expressing various PrP constructs. The mito-
chondrial transmembrane potential (MTP) was used to
comparatively evaluate apoptosis in cells treated with
and without GA. As expected, more green-stained cells
were observed in the HEK293 (Figure 4A) and N2a
(Figure 4B) cells expressing the mutant than in those
expressing wild-type PrPs. There was a significantly
higher percentage of apoptotic cells in the mutant PrP-
expressing cells. In particular, nearly 50% of the cells
expressing Cyto-PrPs were apoptotic (Figure 4C and D).
PrP-induced apoptosis was reversed in cells expressing
Cyto-PrP and PG14-PrP but not 3AV-PrP and ER-PrP
when the cells were treated with 1 μM geldanamycin for
Figure 4 Geldanamycin selectively reversed the apoptosis induced by the cytosolic forms of PrP mutants. A and B. Assays of
mitochondrial dysfunction in the cells expressing various PrP constructs in the presence or absence of geldanamycin. HEK293 cells (A) and N2a
cells (B) expressing various PrP constructs were treated with (GA) or without (Ctrl) geldanamycin, and the mitochondrial transmembrane
transition was evaluated with a commercial kit (as described in the Materials and Methods). Apoptotic and living cells are green and red,
respectively, by fluorescence microscopy. C and D. Quantification of the apoptotic cells. The number of total cells in a field of view was counted
using ImageJ. The percentage of apoptotic cells was defined as the number of green cells vs. the total number of cells.
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PrP-induced apoptosis by enhancing the degradation of
cytosolic PrPs.
Hsp70 proteins are up-regulated in Cyto-PrP-expressing
cells and in the brains of scrapie-infected hamsters
To determine if the accumulation of PrPs in the cytoplasm
affects the expression of endogenous Hsp70, the Cyto-PrP
expression plasmid was introduced into HEK293 cells in
the presence or absence of the proteasomal inhibitor
MG132. We found that the level of Hsp70 detected by
Western blots increased in the cells expressing Cyto-PrP
(Figure 5A and B). In the presence of MG132, the Hsp70-
specific band was much stronger and correlated with the
increase in the Cyto-PrP signal. Treating cells with
MG132 alone did not change the levels of Hsp70
(Figure 5A and B). This finding indicates that the accumu-
lation of cytosolic PrPs in the cytoplasm will increase thelevels of endogenous Hsp70. We next examined the levels
of Hsp70 in the brain tissues of scrapie-infected animals.
For this study, 10% of the brain homogenates of three
scrapie 263K-infected hamsters were used. The gray values
detected by Western blotting were quantitated and nor-
malized to β–actin. We found statistically significant
higher levels of Hsp70 in the brains of the 263K-infected
hamsters compared with the level in normal hamsters
(Figure 5C and D).
Discussion
In the current study, we have demonstrated a molecular
interaction between human PrP and Hsp70. Colocaliza-
tion analyses show that cellular Hsp70 exactly overlaps
with the cytosolic forms of PrPs in cells expressing
Cyto-PrP and PG14-PrP but not wild-type PG5-PrP or
ER-retained PrPs, including 3AV-PrP and ER-PrP. Fur-
thermore, we demonstrate that activation of cellular
Figure 5 Hsp70 proteins are up-regulated in HEK293 cells expressing Cyto-PrP and in the brains of scrapie-infected hamsters. A.
Western blots of PrP and Hsp70 in cells expressing Cyto-PrP treated with or without MG132 (10 μM) for 4 h. The cell lysates were separated by
12% SDS-PAGE, transferred onto a nitrocellulose membrane and analyzed by immunoblotting with antibodies against PrP, Hsp70 or actin. B.
Quantification of the immunoblots. The numerical gray values for PrP or Hsp70 were quantified and normalized to β-actin levels. All experiments
presented in the figures were repeated independently 3 times with consistent results. Each data point represents the mean ± SEM of 3
independent experiments. C. Western blots of PrP and Hsp70 in the brain tissues of normal and scrapie 263K-infected hamsters. Ten percent of
the brain homogenates from each animal was separated by 12% SDS-PAGE and blotted with antibodies against PrP, Hsp70 and actin. D. The
numerical gray values for PrP or Hsp70 were quantified and normalized to β-actin levels. Each data point represents the mean ± SEM of three
animals each group (n = 3).
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pharmacological treatment with geldanamycin, select-
ively promoted the degradation of and restored the rele-
vant cytotoxicity of the cytosolic PrPs but not wild-type
or ER-retained PrPs in cultured cells. These data indicate
that cytosolic PrPs are an authentic substrate of Hsp70.
Hsp70 is a potent molecular chaperone that aids in
the folding and refolding of nascent proteins and dena-
tured proteins, respectively. More importantly, when a
protein cannot be correctly renatured, Hsp70 can medi-
ate degradation of the protein [17,18]. Misfolded/mislo-
calized proteins in the cytoplasm are degraded via the
ubiquitin-proteasome pathway. It has been repeatedly
reported that the overexpression of Hsp70 facilitates the
degradation of α-synuclein [18], a risk factor for PD, and
eliminates the hyperphosphorylated microtubule-associated
protein tau (tau) [17], a primary pathological component of
AD. Therefore, activating Hsp70 is one potential strategy
and therapeutic target for treating AD and PD. Similar to
the abnormal protein deposits found in the brains of
patients with AD and PD, the accumulation of PrPSc in the
brain is a predominant neuropathological feature of prion
diseases. However, numerous evidence has suggested that
PrPSc is not toxic; however, based on experiments incultured cells and transgenic mice, abnormal PrPs, e.g.,
Cyto-PrP [5] or PrPs mutated in the transmembrane region
[12] or in the octarepeat region [4], have been proposed to
be neurotoxic. These data highlight the importance of
clearing continuously produced misfolded PrPs that might
be intermediates of PrPSc. Hsp70 may work as an efficient
host factor to clear toxic misfolded or mislocalized PrPs in
the cytoplasm.
Our results indicate that the accumulation of cytosolic
PrPs increases the levels of cellular Hsp70, which may
reflect a triggered mechanism for cell defense. Addition-
ally, our study shows that Hsp70 is significantly activated
in the brains of scrapie-infected hamsters, which is con-
sistent with what has been observed in the brain tissues
of CJD patients and in animal models of TSE [19]. Al-
though PrPSc is more protease-resistant and cannot be
degraded via the Hsp70-mediated ubiquitin-proteasome
dependent pathway, several studies have demonstrated
that PrPSc can translocate into the cytosol of prion-
infected cells and induce toxicity [20,21]. Up-regulating
Hsp70 in cells would help clear out the penetrated PrPSc
or newly formed prion intermediates.
Hsp70 is usually present in the cytoplasm and med-
iates the efficient modification of misfolded/mislocalized
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function is highly location specific because Hsp70 did
not affect PrP proteins that retain or accumulate in ER.
Correlated with the induced degradation of cytosolic PrPs,
the viability of cells expressing the cytosolic PrP mutants
is markedly improved. Recently, Fernandez-Funez et al.
have described that the wild-type PrP can spontaneously
convert into an insoluble protease-sensitive isoform in
neurons of the transgenic fly brain expressing wild-type
hamaster PrP, meanwhile, over-expression of Hsp70 is
capable of preventing the accumulation of PrPSc-like con-
formers and reducing the neurotoxicity, which suggest
that Hsp70 may be a therapeutic candidate for prion dis-
eases [22]. However, the complexes of Hsp70 and PrP is
detectable in the fraction of membrane microdomains of
aged flies’ brains, which seems to be distinct from the data
in this study. The exact reason for this discrepancy
remains unknown. Hsp70 usually presents in the cyto-
plasm of mammalian cells [23]. Similarly, Hsp70 is mainly
observed in the cytoplasm in the young transgenic PrP
flies, but detected also in the microsome of the old flies.
Probably due to the wide distribution of transgenic PrP
protein in the membrane microdomains in the flies, it
eventually forms a stress along with the spontaneous
conversion. In that situation, Hsp70 moves across the
membranous structures and into organelles. In fact, the
stress-caused shift of Hsp70 from cytoplasm to membrane
has been already described. In our experimental condition,
the PrP constructs located mainly in membrane and organ-
elle (ER) are transiently expressed, which may be too short
to induce such “stress”. That might explain why no com-
plex of PrP-Hsp70 is detected in the fraction of membrane/
organelles. Additionally, our data also illustrate an increased
Hsp70 level in the brains of scrapie strain 263K-infected
hamsters. Further assays of co-localization of PrP and
Hsp70 in subcellular organelles, as well as in different
fractions of brain homogenates will supply more solid
conclusion. Moreover, evidence suggests that the conver-
sion of Hsp70’s function in protein-folding to its function
as a degradation factor is mediated by the co-chaperone
CHIP [24]. A range of cellular agents, e.g., glucocorticoid
receptor [25], ErbB2 [26] and tau [27], are known sub-
strates of CHIP. Additionally, DnaJ (Hsp40) is thought to
link the Hsp70 chaperone machine to the ubiquitin-
proteasome system [28]. The potential contributions of
CHIP and Hsp40 to the Hsp70-mediated protection
against PrP-neurotoxicity will be a valuable research topic.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
JZ, KW and YG performed transfection, Western blot, IHC, IP and drafting the
manuscript. QS, CT, CC, and CG constructed the various PrP plasmids. BYZ
contributed to collection of animal samples. XPD designed the study andcritically revised the manuscript. All of the authors read and approved the
final version of the manuscript.
Acknowledgements
We deeply thank Ms. Huiyin Jiang for her excellent technical support. This
work was supported by the Chinese National Natural Science Foundation
Grant (81100980, 81101302 and 31100117), the National Basic Research
Program of China (973 Program) (2007CB310505) and the SKLID (State Key
Laboratory for Infectious Disease Prevention and Control) Development
Grant (2008SKLID102, 2011SKLID204 and 2011SKLID211).
Received: 27 February 2012 Accepted: 29 November 2012
Published: 6 December 2012
References
1. Prusiner SB: Prions. Proc Natl Acad Sci USA 1998, 95:13363–13383.
2. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, Collinge J: Species-
barrier-independent prion replication in apparently resistant species.
Proc Natl Acad Sci USA 2000, 97:10248–10253.
3. Harris DA, True HL: New insights into prion structure and toxicity. Neuron
2006, 50:353–357.
4. Medrano AZ, Barmada SJ, Biasini E, Harris DA: GFP-tagged mutant prion
protein forms intra-axonal aggregates in transgenic mice. Neurobiol Dis
2008, 31:20–32.
5. Ma J, Wollmann R, Lindquist S: Neurotoxicity and neurodegeneration
when PrP accumulates in the cytosol. Science 2002, 298:1781–1785.
6. Stewart RS, Piccardo P, Ghetti B, Harris DA: Neurodegenerative illness in
transgenic mice expressing a transmembrane form of the prion protein.
J Neurosci 2005, 25:3469–3477.
7. Friant S, Meier KD, Riezman H: Increased ubiquitin-dependent
degradation can replace the essential requirement for heat shock
protein induction. EMBO J 2003, 22:3783–3791.
8. Lanneau D, Wettstein G, Bonniaud P, Garrido C: Heat shock proteins: cell
protection through protein triage. Sci World J 2010, 10:1543–1552.
9. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK,
Greengard P, Xu H: Chaperones increase association of tau protein with
microtubules. Proc Natl Acad Sci USA 2003, 100:721–726.
10. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD,
Veal JM, Steed PM, Hyman BT, McLean PJ: Brain-permeable small-molecule
inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and
rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther 2010,
332:849–857.
11. Wacker JL, Huang SY, Steele AD, Aron R, Lotz GP, Nguyen Q, Giorgini F,
Roberson ED, Lindquist S, Masliah E, Muchowski PJ: Loss of Hsp70
exacerbates pathogenesis but not levels of fibrillar aggregates in a
mouse model of Huntington's disease. J Neurosci 2009, 29:9104–9114.
12. Wang X, Shi Q, Xu K, Gao C, Chen C, Li XL, Wang GR, Tian C, Han J, Dong
XP: Familial CJD associated PrP mutants within transmembrane region
induced Ctm-PrP retention in ER and triggered apoptosis by ER stress in
SH-SY5Y cells. PLoS One 2011, 6:e14602.
13. Zeng XC, Bhasin S, Wu X, Lee JG, Maffi S, Nichols CJ, Lee KJ, Taylor JP,
Greene LE, Eisenberg E: Hsp70 dynamics in vivo: effect of heat shock and
protein aggregation. J Cell Sci 2004, 117:4991–5000.
14. Yao HL, Han J, Gao JM, Zhang J, Zhang BY, Guo YJ, Nie K, Gao C, Wang XF,
Dong XP: Comparative study of the effects of several chemical and
physical treatments on the activity of protease resistance and infectivity
of scrapie strain 263K. J Vet Med B Infect Dis Vet Public Health 2005,
52:437–443.
15. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP: Crystal
structure of an Hsp90-geldanamycin complex: targeting of a protein
chaperone by an antitumor agent. Cell 1997, 89:239–250.
16. Liu W, Chen Y, Lu G, Sun L, Si J: Down-regulation of HSP70 sensitizes
gastric epithelial cells to apoptosis and growth retardation triggered by
H. pylori. BMC Gastroenterol 2011, 11:146.
17. Jinwal UK, Miyata Y, Koren J 3rd, Jones JR, Trotter JH, Chang L, O'Leary J,
Morgan D, Lee DC, Shults CL, et al: Chemical manipulation of hsp70
ATPase activity regulates tau stability. J Neurosci 2009, 29:12079–12088.
18. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ: Hsp70 Reduces alpha-
Synuclein Aggregation and Toxicity. J Biol Chem 2004, 279:25497–25502.
19. Kenward N, Hope J, Landon M, Mayer RJ: Expression of polyubiquitin and
heat-shock protein 70 genes increases in the later stages of disease
Zhang et al. Virology Journal 2012, 9:303 Page 10 of 10
http://www.virologyj.com/content/9/1/303progression in scrapie-infected mouse brain. J Neurochem 1994,
62:1870–1877.
20. Tatzelt J, Winklhofer KF: Folding and misfolding of the prion protein in
the secretory pathway. Amyloid 2004, 11:162–172.
21. Kiachopoulos S, Heske J, Tatzelt J, Winklhofer KF: Misfolding of the prion
protein at the plasma membrane induces endocytosis, intracellular
retention and degradation. Traffic 2004, 5:426–436.
22. Fernandez-Funez P, Casas-Tinto S, Zhang Y, Gomez-Velazquez M, Morales-
Garza MA, Cepeda-Nieto AC, Castilla J, Soto C, Rincon-Limas DE: In vivo
generation of neurotoxic prion protein: role for hsp70 in accumulation
of misfolded isoforms. PLoS Genet 2009, 5:e1000507.
23. Deuerling E, Bukau B: Chaperone-assisted folding of newly synthesized
proteins in the cytosol. Crit Rev Biochem Mol Biol 2004, 39:261–277.
24. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M,
McGowan E, Lewis J, Prihar G, et al: CHIP and Hsp70 regulate tau
ubiquitination, degradation and aggregation. Hum Mol Genet 2004,
13:703–714.
25. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, Patterson C:
The co-chaperone CHIP regulates protein triage decisions mediated by
heat-shock proteins. Nat Cell Biol 2001, 3:93–96.
26. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA,
Wazer DE, Band V, Band H: ErbB2 degradation mediated by the co-
chaperone protein CHIP. J Biol Chem 2003, 278:13829–13837.
27. Shimura H, Schwartz D, Gygi SP, Kosik KS: CHIP-Hsc70 complex
ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem
2004, 279:4869–4876.
28. Chapple JP, van der Spuy J, Poopalasundaram S, Cheetham ME: Neuronal
DnaJ proteins HSJ1a and HSJ1b: a role in linking the Hsp70 chaperone
machine to the ubiquitin-proteasome system? Biochem Soc Trans 2004,
32:640–642.
doi:10.1186/1743-422X-9-303
Cite this article as: Zhang et al.: Heat shock protein 70 selectively
mediates the degradation of cytosolic PrPs and restores the cytosolic
PrP-induced cytotoxicity via a molecular interaction. Virology Journal
2012 9:303.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
